Addressing Resistant Pseudomonas aeruginosa Infections

Pranita Tamma, MD, MHS, discusses the motivations comparing ceftolozane-tazobactam and ceftazidime-avibactam and findings of one observational study.

Results from a recent study comparing ceftolozane-tazobactam and ceftazidime-avibactam for difficult-to-treat Pseudomonas aeruginosa infections found no statistically significant difference in resistance emergence but a surprising numerical trend favoring ceftazidime-avibactam. Pranita Tamma, MD, MHS, continues her conversation about this topic.

Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses the usage of inverse probability weighting with propensity scores to balance patient groups and limit bias.

Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses how clinicians can help reduce the emergence of antimicrobial resistance by using higher doses with extended infusions, limiting treatment duration, ensuring source control, and avoiding unnecessary dose reductions during CRRT.

Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses how an analysis of infection source and treatment patterns found no evidence that combination therapy improves outcomes in patients with drug-resistant Pseudomonas, consistent with prior studies and clinical trials.

Pranita Tamma, MD, MHS, discusses recent studies comparing ceftolozane-tazobactam and ceftazidime-avibactam for drug-resistant Pseudomonas infections, emphasizing similar mortality outcomes, high rates of emerging resistance, and the importance of stewardship practices that prioritize preserving ceftazidime-avibactam for broader clinical use.